NPI 1437145471: Open Payments
NPI 1437145471. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$281 in 10 payments from 5 companies in 2025. Trend: 2023 $846 · 2024 $538 · 2025 $281
Food & beverage: $281
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $150 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Corium, LLC | 1 | $18 |
Products named: Auvelity, REXULTI, TRINTELLIX, SPRAVATO, Azstarys.
